Plain-English translation of NCT05206877 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This Phase 1 trial is testing whether topical sterile human recombinant insulin — insulin delivered as eye drops — can safely help people with optic nerve diseases like glaucoma. Researchers want to find the right dose and frequency that is safe and well-tolerated over 1–2 months. The insulin is being tested because it may protect nerve cells in the eye that are damaged by these conditions.
Glaucoma and other optic nerve diseases can lead to permanent vision loss or blindness, and current treatments don't work for everyone. This trial explores whether this medication might offer a new way to protect the optic nerve and slow vision loss.
You likely qualify if…
You likely don't qualify if…
You will be assigned to one of six groups testing different doses and schedules of the eye drops. Some participants will use the drops in the clinic for 5 days under supervision, while others will take them at home for 1 month. Before and after treatment, you'll undergo eye tests to check your vision and eye health. The entire study lasts 1–2 months, with one eye being treated while the other serves as a control.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States
Safety & dosing
Sponsor
Stanford University
Enrollment target
~52 participants
Started
April 2022
Primary completion
December 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in November 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Mariana Nunez, MD
Stanford University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.